nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
|
Cortesi, Laura |
|
|
16 |
3 |
p. 255-282 |
artikel |
2 |
Coming of Age of Immunotherapy of Urothelial Cancer
|
Grande, Enrique |
|
|
16 |
3 |
p. 283-294 |
artikel |
3 |
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
|
Munoz, Javier |
|
|
16 |
3 |
p. 295-308 |
artikel |
4 |
Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
|
Patelli, Giorgio |
|
|
16 |
3 |
p. 413 |
artikel |
5 |
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
|
Bang, Yeonghak |
|
|
16 |
3 |
p. 411-412 |
artikel |
6 |
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
|
Patelli, Giorgio |
|
|
16 |
3 |
p. 309-324 |
artikel |
7 |
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer
|
Meyrick, Danielle |
|
|
16 |
3 |
p. 369-380 |
artikel |
8 |
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
|
Bjartell, Anders |
|
|
16 |
3 |
p. 357-367 |
artikel |
9 |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
|
Yoh, Kiyotaka |
|
|
16 |
3 |
p. 339-355 |
artikel |
10 |
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
|
Bang, Yeonghak |
|
|
16 |
3 |
p. 401-410 |
artikel |
11 |
Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
|
Akinduro, Oluwaseun O. |
|
|
16 |
3 |
p. 325-337 |
artikel |
12 |
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
|
Aparicio, Thomas |
|
|
16 |
3 |
p. 381-388 |
artikel |
13 |
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
|
Bazhenova, Lyudmila |
|
|
16 |
3 |
p. 389-399 |
artikel |